Development of technologies for evaluation of antibody response following Coronavirus Infection vs Vaccination to identify immune correlates of protection

武汉新冠状病毒(NCoV)的出现引发了迅速开发有效的医学对策的努力，包括针对这种严重疾病的疫苗和治疗方法。然而，关于接种疫苗或在动物或人类中感染nCoV后产生的多克隆抗体反应的知识有限。重要的是要确定和了解免疫标志物，这些免疫标志物合理地可能预测临床益处，并可以促进对疫苗和候选治疗的评估，包括： 不同的疫苗平台在人与动物的抗体表位谱、抗体同型、抗体亲和力和持久性方面是否相似或不同？ 针对nCoV：总抗体与刺突蛋白中特定抗原区结合的保护性相关因素是什么？抗体亲和力？抗体同型？抗体表位多样性？ NCoV疫苗产生的抗体的数量、质量(表位和亲和力)和持久性与感染后(急性和恢复期)血清中的抗体相似还是不同？ 为了解决这些差距，我们将开发先进的技术，包括用于新型冠状病毒(NCoV)的全基因组噬菌体展示文库(GFPDL)和SPR，以深入分析动物模型或人类接种疫苗和nCoV感染后的免疫反应。

The emergence of the Wuhan new coronavirus (nCoV) initiated efforts to rapidly develop effective medical countermeasures including vaccines and therapeutics against this severe disease. However, there is limited knowledge on polyclonal antibody responses generated following vaccination or nCoV infection in animals or humans. It is important to identify and understand immune markers that are reasonably likely to predict clinical benefit and that can facilitate evaluation of vaccine and therapeutic candidates, including: I. Do different vaccine platforms elicit similar or different antibody epitope repertoires, antibody isotypes, antibody affinity and durability in human’s vs animals? II. What are the correlates of protection against nCoV: Total antibody binding to specific antigenic regions within spike protein? antibody affinity? antibody isotype? antibody epitope diversity? III. Is the quantity, quality (epitopes and affinity) and durability of antibodies generated by nCoV- vaccination is similar or different than those of antibodies found in post-infection (in acute and convalescent) sera? To address these gaps, we will develop advanced technologies, including whole genome phage display library (GFPDL) and SPR for the new Coronavirus (nCoV) for in-depth analysis of immune responses following vaccination and nCoV infection in animal models or humans.